Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia.
Blood., Jun;119(25):5989-95 (2012)
Cancer Treat. Res., 157:289-303 (2011)
Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities.
Mod. Pathol., Jan;25(1):65-74 (2012)
Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.
Br. J. Haematol., Oct;155(2):248-55 (2011)
Cytomegalovirus can make immune thrombocytopenic purpura refractory.
Br. J. Haematol., Jun;146(1):104-12 (2009)
Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy.
J. Acquir. Immune Defic. Syndr., Dec;52(5):595-9 (2009)
Traditional and new approaches to the management of immune thrombocytopenia: issues of when and who to treat.
Hematol. Oncol. Clin. North Am., Dec;23(6):1329-41 (2009)
Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus.
Am. J. Obstet. Gynecol., Aug;203(2):135.e1-14 (2010)
Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk.
Blood., Apr;113(14):3154-60 (2009)
Current approaches to the evaluation and management of the fetus and neonate with immune thrombocytopenia.
Semin. Perinatol., Feb;33(1):35-42 (2009)
Therapeutic approaches to secondary immune thrombocytopenic purpura.
Semin. Hematol., Jan;46(1 Suppl 2):S44-58 (2009)
Refractory immune thrombocytopenic purpura: current strategies for investigation and management.
Br. J. Haematol., Oct;143(1):16-26 (2008)
How effective is eltrombopag for the treatment of thrombocytopenia in patients with HCV infection?
Nat Clin Pract Gastroenterol Hepatol., Aug;5(8):424-5 (2008)
Fc receptors in immune thrombocytopenias: a target for immunomodulation?
J. Clin. Invest., Aug;118(8):2677-81 (2008)
Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura.
Blood., Aug;112(4):1325-8 (2008)
Treatment with rituximab in benign and malignant hematologic disorders in children.
J. Pediatr., Apr;150(4):338-44, 344.e1 (2007)
The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP.
Br. J. Haematol., Jul;138(2):245-8 (2007)
Novel thrombopoietic agents: preliminary activity, potential benefit.
J Support Oncol., Apr;5(4 Suppl 2):63-84 (2007)
CD40 ligand and MHC class II expression are essential for human peripheral B cell tolerance.
J. Exp. Med., Jul;204(7):1583-93 (2007)
Immune thrombocytopenic purpura.
Hematol. Oncol. Clin. North Am., Aug;21(4):743-59, vii (2007)